Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.

Daniel A MorgensternUlrike PötschgerLucas MorenoVassilios PapadakisCormac OwensShifra AshClaudia PasqualiniRoberto LukschAlberto GaraventaAdela CaneteMartin ElliotAleksandra WieczorekGeneviève LaureysPer KognerJosef MalisEllen RuudMaja Beck-PopovicGudrun SchleiermacherDominique Valteau-CouanetRuth Ladenstein

Published in: Pediatric blood & cancer (2018)

A simple score can identify an "ultra-high risk" (UHR) cohort (score = 5) comprising 8% of patients with 5-year EFS <10%. These patients appear not to benefit from induction therapy and could potentially be directed earlier to alternative experimental therapies in future trials.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
squamous cell carcinoma
high resolution
prognostic factors
stem cells
mesenchymal stem cells
cell therapy
smoking cessation